11,636 research outputs found
Recommended from our members
Correction to EM Laboratory Scientific Report No. 40: The Use of Effective Aperture Relations for the Calculation of the Input Conductance of electrically Small Antenna
Looking for New Physics in B --> K^* \pi and B --> \rho K Decays
B --> K^* \pi and B --> \rho K decays involve the same quark-level processes
as B --> \pi K. Analyzing the measurements of the former decays might be able
to shed additional light on the new-physics hints in the current B --> \pi K
data. We perform fits to B --> K^* \pi and B --> \rho K decays, and find that
the data can be accommodated within the standard model. However, this agreement
is due principally to the large errors in the data, particularly the
CP-violating asymmetries. If the errors on the B --> K^* \pi and B --> \rho K
observables can be reduced, one will have a clearer sense of whether new
physics is present in these decays.Comment: 12 pages and 6 plots; version to appear in journa
Energy and Charged Particle Flow in 10.8 A GeV/c Au+Au Collisions
Experimental results and a detailed analysis are presented of the transverse
energy and charged particle azimuthal distributions measured by the E877
collaboration for different centralities of Au+Au collisions at a beam momentum
of 10.8 A GeV/c. The anisotropy of these distributions is studied with respect
to the reaction plane reconstructed on an event-by-event basis using the
transverse energy distribution measured by calorimeters. Results are corrected
for the reaction plane resolution. For semicentral events we observe directed
flow signals of up to ten percent. We observe a stronger anisotropy for slow
charged particles. For both the charged particle and transverse energy
distributions we observe a small but non zero elliptic anisotropy with the
major axis pointing into the reaction plane. Combining the information on
transverse energy and charged particle flow we obtain information on the flow
of nucleons and pions. The data are compared to event generators and the need
to introduce a mean field or nucleon-nucleon potential is discussed.Comment: RevTex, 25 pages, 13 figures included as one Postscript file,
submitted to Phys. Rev.
Limits on Radio Continuum Emission from a Sample of Candidate Contracting Starless Cores
We used the NRAO Very Large Array to search for 3.6 cm continuum emission
from embedded protostars in a sample of 8 nearby ``starless'' cores that show
spectroscopic evidence for infalling motions in molecular emission lines. We
detect a total of 13 compact sources in the eight observed fields to 5 sigma
limiting flux levels of typically 0.09 mJy. None of these sources lie within 1'
of the central positions of the cores, and they are all likely background
objects. Based on an extrapolation of the empirical correlation between the
bolometric luminosity and 3.6 cm luminosity for the youngest protostars, these
null-detections place upper limits of ~0.1 L_sun (d/140pc)^2 on the
luminosities of protostellar sources embedded within these cores. These limits,
together with the extended nature of the inward motions inferred from molecular
line mapping (Lee et al. 2001), are inconsistent with the inside-out collapse
model of singular isothermal spheres and suggest a less centrally condensed
phase of core evolution during the earliest stages of star formation.Comment: Accepted to the Astronomical Journal; 12 pages, 1 figur
Recommended from our members
Supplement to EM Laboratory Scientific Report No.20: Simple Expressions for Current on a Thin Cylindrical Receiving Antenna
Chemoenzymatic Probes for Detecting and Imaging Fucose-α(1-2)-galactose Glycan Biomarkers
The disaccharide motif fucose-α(1-2)-galactose (Fucα(1-2)Gal) is involved in many important physiological processes, such as learning and memory, inflammation, asthma, and tumorigenesis. However, the size and structural complexity of Fucα(1-2)Gal-containing glycans have posed a significant challenge to their detection. We report a new chemoenzymatic strategy for the rapid, sensitive detection of Fucα(1-2)Gal glycans. We demonstrate that the approach is highly selective for the Fucα(1-2)Gal motif, detects a variety of complex glycans and glycoproteins, and can be used to profile the relative abundance of the motif on live cells, discriminating malignant from normal cells. This approach represents a new potential strategy for biomarker detection and expands the technologies available for understanding the roles of this important class of carbohydrates in physiology and disease
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
BackgroundThe large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).MethodsPROCEED enrolled patients with mCRPC receiving 3 biweekly sipuleucel-T infusions. Assessments included overall survival (OS), serious adverse events (SAEs), cerebrovascular events (CVEs), and anticancer interventions (ACIs). Follow-up was for ≥3 years or until death or study withdrawal.ResultsIn 2011-2017, 1976 patients were followed for 46.6 months (median). The median age was 72 years, and the baseline median prostate-specific antigen level was 15.0 ng/mL; 86.7% were white, and 11.6% were African American. Among the patients, 1902 had 1 or more sipuleucel-T infusions. The median OS was 30.7 months (95% confidence interval [CI], 28.6-32.2 months). Known prognostic factors were independently associated with OS in a multivariable analysis. Among the 1255 patients who died, 964 (76.8%) died of prostate cancer (PC) progression. The median time from the first infusion to PC death was 42.7 months (95% CI, 39.4-46.2 months). The incidence of sipuleucel-T-related SAEs was 3.9%. The incidence of CVEs was 2.8%, and the rate per 100 person-years was 1.2 (95% CI, 0.9-1.6). The CVE incidence among 11,972 patients with mCRPC from the Surveillance, Epidemiology, and End Results-Medicare database was 2.8%; the rate per 100 person-years was 1.5 (95% CI, 1.4-1.7). One or more ACIs (abiraterone, enzalutamide, docetaxel, cabazitaxel, or radium 223) were received by 77.1% of the patients after sipuleucel-T; 32.5% and 17.4% of the patients experienced 1- and 2-year treatment-free intervals, respectively.ConclusionsPROCEED provides contemporary survival data for sipuleucel-T-treated men in a real-world setting of new life-prolonging agents, which will be useful in discussing treatment options with patients and in powering future trials with sipuleucel-T. The safety and tolerability of sipuleucel-T in PROCEED were consistent with previous findings
- …